Research news

The latest developments in the search for better treatments and a cure for macular disease.

Latest news

Andrew Lotery using optometrist equipment. Andrew is wearing blue scrubs and glasses and has dark short hair.

Professor Andrew Lotery answers your questions

Posted: Wednesday 5 March 2025

Professor Andrew Lotery discusses the latest approved treatment for wet age-related macular degeneration (AMD), Lytenava and answers your frequently asked questions on treatments and research.

Gene therapy trial improves sight in blind toddlers

Posted: Tuesday 4 March 2025

Four toddlers born with a severe form of childhood blindness have experienced “life-changing improvements” to their sight after participating in an experimental gene therapy trial.

Syfovre FAQs and next steps for dry AMD and geographic atrophy treatment

Posted: Thursday 30 January 2025

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) decision to reject the first potential treatment for geographic atrophy (GA), or late-stage age-related macular degeneration (AMD) is undoubtedly a disappointing one for those living with the condition. But, what does the decision mean? We answer your questions.

First treatment for late-stage dry AMD rejected by UK drug regulator

Posted: Wednesday 22 January 2025

The first potential treatment for geographic atrophy (GA) or late stage dry aged-related macular degeneration has been rejected by the Medicines and Healthcare products Regulatory Agency (MHRA).

How artificial intelligence is transforming eye care

Posted: Thursday 9 January 2025

Artificial intelligence (AI) is already part of our daily lives, but how is it changing healthcare? In a recent webinar hosted by Macular Society partner OcuPlan Dr James Neffendorf, an eye specialist at King’s College Hospital and ophthalmic surgeon Dan Calladine, explored how AI is transforming the way eye care is delivered and how it is improving outcomes for patients.

One hand holding a pill bottle tipping the pills out into an open hand, which holds two pills.

Daily tablet shows promise as first treatment for Stargardt disease

Posted: Monday 2 December 2024

A new drug for Stargardt disease, called gildeuretinol (ALK-001), has received special recognition from the Food and Drug Administration in the US, highlighting its potential to treat the condition.

Explore our research

Beating macular disease through funding medical research and improving the lives of those living with macular disease.

Get involved in research

Patients have a very important part to play in medical research. Without them we would not have the treatments we have today and new and improved treatments would not be possible.